Home

Mark J Foley

CIK 1529196 · President & CEO · last filed 2026-06-23

Mark J Foley is a President & CEO who has filed 129 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for GKOS, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$30.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.2M across reported positions. 72 SEC filings were submitted jointly with Zeltiq Aesthetics Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.24M

Companies

4

Total Filings

129

Lifetime Open-Market Net

-$30.04M

Filer Profile

Reported Address
GLAUKOS CORPORATION
1 GLAUKOS WAY
ALISO VIEJO, CA 92656
Related Filers
Zeltiq Aesthetics Inc — 72 joint filings, latest 2017-04-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GKOS Director 60,267 $167.25 $10.08M -$2.92M 19 2026-06-23
Revance Therapeutics, Inc. (RVNC) Delisted President & CEO 27,933 $3.65 $102.0K -$5.60M 34 2025-02-06
SIBN Director 8,797 $18.38 $161.7K $0 2 2020-06-18
Zeltiq Aesthetics Inc (ZLTQ) Delisted President and CEO 0 — — -$21.52M 67 2017-04-28

Recent Filings

129 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 GKOS Grant (A) — $0 EDGAR
2026-06-01 GKOS Grant (A) +1,878 $0 EDGAR
2026-01-07 GKOS Grant (A) +1,168 $0 EDGAR
2025-06-02 GKOS Grant (A) +2,972 $0 EDGAR
2025-02-28 GKOS Mixed +19,313 -$1.33M EDGAR
2025-02-26 GKOS Notice (144) −20,687 -$2.50M EDGAR
2025-02-06 Revance Therapeutics, Inc. (RVNC) Delisted Mixed −1,135,781 -$4.04M EDGAR
2025-02-05 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +27,933 $0 EDGAR
2025-01-03 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +1,000 $2.2K EDGAR
2024-07-02 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +1,000 $2.2K EDGAR
Showing 1–10 of 129
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.